<DOC>
	<DOC>NCT00000344</DOC>
	<brief_summary>The purpose of this study is to determine the efficacy and safety of a buprenorphine/naloxone sublingual tablet formulation as an office-based therapy for opiate-dependence treatment.</brief_summary>
	<brief_title>Buprenorphine/Naloxone for Treatment of Opiate Dependence - 9</brief_title>
	<detailed_description />
	<mesh_term>Opioid-Related Disorders</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Buprenorphine</mesh_term>
	<mesh_term>Buprenorphine, Naloxone Drug Combination</mesh_term>
	<criteria>M/F ages 2150. Meet DSMIV criteria for opiate dependence. Agree to conditions of the study and sign informed consent. Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>opioid dependence</keyword>
</DOC>